






Memorandum Immunology #9

To: UNCHCS Attending Physicians, Housestaff, Clinical Nurse Coordinators,
Department Heads, and Supervisors

From:  John Schmitz, Ph.D.
Director, Immunology Laboratory

 Eric Weimer, Ph.D.
Associate Director, Immunology Laboratory

 Herbert C. Whinna, M.D., Ph.D.
Medical Director, McLendon Clinical Laboratories

Date: October 6, 2021

Subject: Double stranded DNA antibody testing update

Effective October 11, 2021, the Immunology laboratory will implement a change in testing for dsDNA antibody (LAB648). Currently, this testing is performed by indirect immunofluorescence assay using the *Crithidia luciliae* substrate. Serum samples are screened at a 1:10 dilution. Results are reported as negative or positive. Positive sera are further tested in a serial dilution to determine the endpoint titer that is also reported.

The following change in practice is being implemented to optimize workflow and testing costs. If a sample is tests positive it will be serially 2-fold diluted to a 1:640 titer. Samples positive at the 1:640 titer with be reported as Positive, $\geq 1:640$. If an endpoint titer is needed please contact the Immunology laboratory to request an endpoint titer be performed. The Immunology laboratory can be reached at 984-974-1815.